ABBOTT LABORATORIES 8-K

What Happened
Abbott Laboratories (ABT) filed an 8‑K (Apr 17, 2026) reporting that the U.S. District Court for the Northern District of Illinois signed an Order on April 10, 2026 preliminarily approving a proposed settlement in the consolidated case In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation. The filing notes six shareholder derivative lawsuits had been consolidated and previously disclosed in Abbott’s Form 10‑Ks for the fiscal years ended December 31, 2024 and December 31, 2025. Abbott attached a Notice of Proposed Settlement and Final Settlement Hearing as Exhibit 99.1.

Key Details

• Six shareholder derivative lawsuits were consolidated in the Northern District of Illinois under the referenced litigation.
• Court signed the Order preliminarily approving the proposed settlement on April 10, 2026.
• The 8‑K includes Exhibit 99.1: “Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear.”
• The 8‑K does not disclose monetary terms or additional settlement details beyond the court’s preliminary approval and the notice.

Why It Matters
A preliminary approval and notice mean shareholders will be informed and a final settlement hearing is scheduled; the matter moves closer to resolution. For investors, this is a legal and governance development that could affect Abbott’s future disclosures of litigation liabilities or related costs if settlement terms are later disclosed. Monitor future filings (updates to the case, final approval, or financial statements) for any disclosed financial impact or corporate governance actions.